Peripheral arterial disease: Current perspectives and new trends in management

Southern Medical Journal

Volumn 102, Issue 11, 2009, Pages 1141-1149

  Aslam, Farhan ^a   Haque, Attiya ^a   Foody, Joanne ^a   Lee, L Veronica ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Yale Cardiology at the Shoreline   (United States)

Author keywords

ABI; Diabetes; Hypertension; Patients; Peripheral vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DEFIBROTIDE; GINKGO BILOBA EXTRACT; MESOGLYCAN; NAFTIDROFURYL; NEW DRUG; NM 702; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

AGING; ANGIOGENESIS; ANGIOPLASTY; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE THERAPY; ARTHRITIS; ARTIFICIAL EMBOLISM; ATHEROSCLEROSIS; BYPASS SURGERY; CIGARETTE SMOKING; CLINICAL PRACTICE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; COXITIS; DEEP VEIN THROMBOSIS; DIABETES CONTROL; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG CHOICE; DRUG COST; DYSLIPIDEMIA; EXERCISE TEST; GRAFT FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; INTERMITTENT CLAUDICATION; INTERVERTEBRAL DISK HERNIA; LEG PAIN; LEG REVASCULARIZATION; LIFESTYLE MODIFICATION; MAGNETIC RESONANCE ANGIOGRAPHY; NERVE ROOT COMPRESSION; NONHUMAN; PATIENT COUNSELING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PHYSICAL EXAMINATION; PLETHYSMOGRAPHY; PRACTICE GUIDELINE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION; STROKE; TREATMENT OUTCOME; VERTEBRAL CANAL STENOSIS; WOUND INFECTION;

ADULT; AGED; ANKLE BRACHIAL INDEX; HUMANS; LIFE STYLE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 73849095462     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181bb9ab8     Document Type: Review

References (67)

1. Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5-S67. (Pubitemid 46151680)
2. Becker GJ, McClenny TE, Kovacs ME, et al. The importance of increasing public and physician awareness on peripheral artery disease. J Vasc Interv Radiol 2002;13:7-11.
3. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from the Framingham heart study Circulation 1997;96:44-49.
4. Reeder BA, Liu L, Horlick L. Sociodemographic variation in the prevalence of cardiovascular disease. Can J Cardiol 1996;12:271-275.
5. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71: 510-517.
6. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-742.
7. Colins TC, Peterson NJ, Suarez-Almazor M, et al. The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med 2003;163:1469-1474.
8. Gerhard GT, Malinow MR, DeLoughery TG, et al. Higher total homocysteine concentration and lower folate concentrations in premenopausal black women than in premenopausal white women. Am J Clin Nutr 1999;70:252-260.
9. Folsom AR, Wu KK, Conlan MG, et al. Distributions of hemostatic variables in black and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) study. Ethn Dis 1992;2: 35-46.
10. Conlan MG, Folsom AR, Finch A, et al. Associations of Factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 1993;70:380-385.
11. Fowkes FG, Lee AJ, Hou CM, et al. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risk of peripheral arterial disease and coronary heart disease: Edinburgh artery study. Atherosclerosis 2000;150:179-185.
12. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs: the Framingham study JAMA 1972;221:661-666.
13. Lu JT, Creager MA. The relationship of cigarette smoking to peripheral arterial disease. Cardiovasc Med 2004;5:189-193.
14. Beckman J, Creager MA. Management of Peripheral Arterial Disease. London, ReMEDICA publishing, 2000,pp 19-42.
15. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epedimiology, pathophysiology, and management. JAMA 2002 287:2570-2581.
16. Murabito JM, D' Agostino RB, Silbershatz H, et al. Intermittent claudication: a risk profile from the Framingham heart study. Circulation 1997;96:44-49.
17. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham offspring study. Am Heart J 2002;143:961-968.
18. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral artery disease: Importance of identifying the population at risk. Vasc Med 1997;2:221-225.
19. Greenhalgh RM, Rosengarten DS, Mervart I, et al. Serum lipids and lipoproteins in the peripheral vascular disease. Lancet 1971;2:947-950.
20. Bradby GV, Valente AJ, Walton KW. Serum high-density lipoproteins in peripheral vascular disease. Lancet 1978;2:1271-1274.
21. Smith FB, Lee AJ, Hau CM, et al. Plasma fibrinogen, hemostatic factors and prediction of peripheral arterial disease in Edinburgh artery study. Blood Coagul Fibrinolysis 2000;11:43-50.
22. Vidula H, Tian L, Liu K, et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 2008;148:85-93.
23. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
24. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-2879.
25. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286:1599-1606.
26. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463-e654.
27. Mcgee SR, Boyko EJ. Physical examination and chronic lower-extremity ischemia: a critical review. Arch Intern Med 1998;158:1357-1364.
28. Criqui MH, Fronek A, Klauber MR, et al. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation 1985;71:516-522.
29. Ouriel K. Peripheral arterial disease. Lancet 2001;358:1257-1264.
30. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-892.
31. Vogt MT, Cauley JA, Newman AB, et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993;270:465-469.
32. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong heart study. Circulation 2004;109:733-739.
33. Darling RC, Raines JK, Brener BJ, et al. Quantitative segmental pulse volume recorder: a clinical tool. Surgery 1972;72:873-877.
34. Ho KY, de Hann MW, Kessels AG, et al. Peripheral vascular tree stenoses: detection with substracted and nonsubstracted MR angiography. Radiology 1998;206:673-681.
35. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362.
36. Grobner T. Gadolinium, a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
37. Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg 1982;(69 suppl): S24-S26.
38. Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987;221: 253-260.
39. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;(45 suppl S): S5-S67. (Pubitemid 46151680)
40. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
41. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet 1998;352:837-853.
42. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
43. ADVANCE Collaborative Group; Patel M, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
44. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151:1769-1776.
45. Thadani U, Whitsett TL. Beta-adrenergic blockers and intermittent claudication. Time for reappraisal. Arch Intern Med 1991;151:1705-1707.
46. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000;2:CD000990.
47. Garg PK, Tian L, Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation 2006; 114:242-248. (Pubitemid 44297117)
48. Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710-713
49. Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992;340:143-145.
50. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.
51. Reilly MP, Mohler ER III. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35:48-56.
52. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314-1319.
53. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:609S- 626S.
54. Lehert P, Comte S, Gamand S, et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994; 23(suppl 3):S48-S52.
55. Moody AP, al-Khaffaf HS, Lehert P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994;23(suppl 3):S44-S47.
56. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999;159:337-345.
57. Avellone G, Mandalà V, Pinto A, et al. Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs. Haemostasis 1986;16(suppl 1):55-58.
58. Brass EP, Anthony R, Cobb FR, et al. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006;48: 2539-2545.
59. Nenci GG, Gresele P, Ferrari G, et al; Mesoglycan Intermittent Claudication group. Treatment of intermittent claudication with mesoglycan-a placebo-controlled, double-blind study. Thromb Haemost 2001;86:1181-1187.
60. Takeshita S, Zheung LP, Brogi E, et al. Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest 1994;93:662-670.
61. Lederman RJ, Mendelsohn FO, Anderson RD, et al; TRAFFIC investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053-2058.
62. Rajagopalan S, Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-1938.
63. Wolf GL, Wilson SE, Cross AP, et al. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. J Vasc Interv Radiol 1993;4:639-648.
64. Gardiner GA Jr, Meyerovitz MF, Stokes KR, et al. Complications of transluminal angioplasty. Radiology 1986;159:201-208.
65. Vroegindeweij D, Vos LD, Tielbeek AV, et al. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol 1997;20:420-425.
66. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions. A randomized controlled study. Int Angiol 1999;18:251-255.
67. DeBakey ME, Glaeser DH. Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. Am J Cardiol 2000;85:1045-1053.